Oculis to Participate in Upcoming September Investor Conferences
Oculis (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases, announced its participation in five major investor conferences during September 2025.
Key presentations include:
- Wells Fargo Healthcare Conference (Sept 3-5, Boston)
- H.C. Wainwright Global Investment Conference (Sept 8-10, New York) - Fireside chat on Sept 8 at 2:30 PM ET
- Baird Global Healthcare Conference (Sept 9-10, New York) - Company update on Sept 9 at 3:45 PM ET
- Pareto Securities Healthcare Conference (Sept 16, Stockholm) - Update at 9:15 AM CET
- Leerink Partners Biopharma Summit (Sept 17-19, Healdsburg)
Oculis (Nasdaq: OCS), societ脿 biofarmaceutica globale specializzata in patologie oftalmiche e neuro-oftalmiche, ha comunicato la propria partecipazione a cinque importanti conferenze per investitori previste per settembre 2025.
Le presentazioni principali includono:
- Wells Fargo Healthcare Conference (3-5 settembre, Boston)
- H.C. Wainwright Global Investment Conference (8-10 settembre, New York) - Fireside chat l'8 settembre alle 14:30 ET
- Baird Global Healthcare Conference (9-10 settembre, New York) - Aggiornamento aziendale il 9 settembre alle 15:45 ET
- Pareto Securities Healthcare Conference (16 settembre, Stoccolma) - Aggiornamento alle 09:15 CET
- Leerink Partners Biopharma Summit (17-19 settembre, Healdsburg)
Oculis (Nasdaq: OCS), una compa帽铆a biofarmac茅utica global especializada en enfermedades oft谩lmicas y neuro-oft谩lmicas, anunci贸 su participaci贸n en cinco importantes conferencias para inversores durante septiembre de 2025.
Las presentaciones clave incluyen:
- Wells Fargo Healthcare Conference (3-5 de septiembre, Boston)
- H.C. Wainwright Global Investment Conference (8-10 de septiembre, Nueva York) - Fireside chat el 8 de septiembre a las 2:30 PM ET
- Baird Global Healthcare Conference (9-10 de septiembre, Nueva York) - Actualizaci贸n de la compa帽铆a el 9 de septiembre a las 3:45 PM ET
- Pareto Securities Healthcare Conference (16 de septiembre, Estocolmo) - Actualizaci贸n a las 9:15 AM CET
- Leerink Partners Biopharma Summit (17-19 de septiembre, Healdsburg)
Oculis (Nasdaq: OCS)電� 鞎堦臣 氚� 鞁犼步鞎堦臣 歆堩櫂鞚� 鞝勲鞙茧 頃橂姅 旮�搿滊矊 氚旍澊鞓れ牅鞎届偓搿�, 2025雲� 9鞗旍棎 臧滌禍霅橂姅 5臧滌潣 欤检殧 韴瀽鞛� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
欤检殧 氚滍憸 鞚检爼鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:
- Wells Fargo Healthcare Conference (9鞗� 3-5鞚�, 氤挫姢韯�)
- H.C. Wainwright Global Investment Conference (9鞗� 8-10鞚�, 雺挫殨) - 9鞗� 8鞚� 鞓ろ泟 2:30(霃欕秬 鞁滉皠)鞐� 韺岇澊鞏挫偓鞚措摐 毂勴姼
- Baird Global Healthcare Conference (9鞗� 9-10鞚�, 雺挫殨) - 9鞗� 9鞚� 鞓ろ泟 3:45(霃欕秬 鞁滉皠)鞐� 須岇偓 鞐呺嵃鞚错姼
- Pareto Securities Healthcare Conference (9鞗� 16鞚�, 鞀ろ啞頇�毽�) - 鞓れ爠 9:15(CET)鞐� 鞐呺嵃鞚错姼
- Leerink Partners Biopharma Summit (9鞗� 17-19鞚�, 頌愳氩勱犯)
Oculis (Nasdaq: OCS), une soci茅t茅 biopharmaceutique mondiale sp茅cialis茅e dans les maladies ophtalmiques et neuro-ophtalmiques, a annonc茅 sa participation 脿 cinq grandes conf茅rences investisseurs en septembre 2025.
Les pr茅sentations principales comprennent :
- Wells Fargo Healthcare Conference (3-5 septembre, Boston)
- H.C. Wainwright Global Investment Conference (8-10 septembre, New York) - Fireside chat le 8 septembre 脿 14h30 ET
- Baird Global Healthcare Conference (9-10 septembre, New York) - Mise 脿 jour de l'entreprise le 9 septembre 脿 15h45 ET
- Pareto Securities Healthcare Conference (16 septembre, Stockholm) - Mise 脿 jour 脿 09h15 CET
- Leerink Partners Biopharma Summit (17-19 septembre, Healdsburg)
Oculis (Nasdaq: OCS), ein globales biopharmazeutisches Unternehmen, das sich auf ophthalmologische und neuro鈥憃phthalmologische Erkrankungen spezialisiert hat, gab seine Teilnahme an f眉nf wichtigen Investorenkonferenzen im September 2025 bekannt.
Wesentliche Pr盲sentationen umfassen:
- Wells Fargo Healthcare Conference (3.鈥�5. September, Boston)
- H.C. Wainwright Global Investment Conference (8.鈥�10. September, New York) - Fireside-Chat am 8. September um 14:30 Uhr ET
- Baird Global Healthcare Conference (9.鈥�10. September, New York) - Unternehmensupdate am 9. September um 15:45 Uhr ET
- Pareto Securities Healthcare Conference (16. September, Stockholm) - Update um 09:15 Uhr CET
- Leerink Partners Biopharma Summit (17.鈥�19. September, Healdsburg)
- None.
- None.
ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (鈥淥culis鈥�), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis鈥� management will participate in upcoming investor conferences in September.
Wells Fargo Healthcare Conference
September 3-5; Boston, U.S.
Riad Sherif, M.D., Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer, will attend.
H.C. Wainwright 27th Annual Global Investment Conference
September 8-10; New York, U.S.
Fireside chat with Riad Sherif, M.D., Chief Executive Officer, scheduled for September 8th at 2:30 pm ET.
Webcast Link:
Baird Global Healthcare Conference
September 9-10; New York, U.S.
Company update with Riad Sherif, M.D., Chief Executive Officer, scheduled for September 9th at 3:45 pm ET.
Webcast Link:
Pareto Securities 16th Annual Healthcare Conference
September 16; Stockholm, Sweden
Company update with P谩ll Ragnar J贸hannesson, Chief Business Officer, scheduled for September 16th at 9:15 am CET.
Leerink Partners Biopharma Summit
September 17-19; Healdsburg, U.S.
Riad Sherif, M.D., Chief Executive Officer, will attend.
The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.
Webcast links, when available, will be posted to the Oculis website on the聽聽page under the Investors & Media section.
-END-
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. Oculis鈥� highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potentially broad clinical applications in various neuro-ophthalmic and neurological diseases; and Licaminlimab (OCS-02), a novel topical anti-TNF伪 in Phase 2, being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit:
Oculis Contacts
Ms. Sylvia Cheung, CFO
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
FAQ
When is Oculis (OCS) presenting at the H.C. Wainwright Conference 2025?
How can investors schedule meetings with Oculis management at the September 2025 conferences?
Where can I watch the webcasts of Oculis (OCS) September 2025 conference presentations?
Which Oculis executives are attending the Wells Fargo Healthcare Conference 2025?
